PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer
暂无分享,去创建一个
John M. S. Bartlett | Stefan Michiels | Christos Sotiriou | Sherene Loi | C. Sotiriou | S. Loi | M. Piccart | J. Baselga | J. Bartlett | S. Michiels | A. Sims | S. Singhal | Jose Baselga | V. Sabine | T. Sahmoud | J. Dixon | Sandeep K. Singhal | Vicky S. Sabine | Andrew H. Sims | Tarek Sahmoud | J. Michael Dixon | Martine J. Piccart
[1] I. Ray-Coquard,et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Piccart,et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.
[3] Rosette Lidereau,et al. PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups , 2012, Breast Cancer Research.
[4] J. Bartlett,et al. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study , 2011, Breast Cancer Research and Treatment.
[5] M. Dowsett,et al. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer , 2010, Breast Cancer Research.
[6] Francesca Molinari,et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. , 2010, The Journal of clinical investigation.
[7] J. Dixon,et al. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer , 2010, Breast Cancer Research and Treatment.
[8] Paul Ellis,et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer , 2010, Proceedings of the National Academy of Sciences.
[9] M. Belvin,et al. Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models , 2010, Clinical Cancer Research.
[10] H. Lane,et al. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells , 2009, Proceedings of the National Academy of Sciences.
[11] W. Gerald,et al. PIK3CA Mutation Associates with Improved Outcome in Breast Cancer , 2009, Clinical Cancer Research.
[12] Jeffrey A. Engelman,et al. Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.
[13] R. Greil,et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Olson,et al. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer , 2009, Breast Cancer Research and Treatment.
[15] Jingqin Luo,et al. Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics , 2008, Journal of the National Cancer Institute.
[16] Hans E. Huber,et al. Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling , 2008, PloS one.
[17] Mitch Dowsett,et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.
[18] D. Whyte,et al. Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. , 2006, Biochemical and biophysical research communications.
[19] M. Dowsett,et al. Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer , 2006, Clinical Cancer Research.
[20] Yiling Lu,et al. Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.
[21] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.
[22] Shiuan Chen,et al. Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer , 2005, Clinical Cancer Research.